Frovatriptan plus dexketoprofen in the treatment of menstrually related migraine: an open study

At least 50 % of female migraineurs experience migraine associated with the perimenstrual period, even though they may also suffer from attacks at other times of the cycle (menstrually related migraine, MRM). MRM attacks tend to be longer and more intense than those arising in other phases of the me...

Full description

Saved in:
Bibliographic Details
Published in:Neurological sciences 2013-05, Vol.34 (Suppl 1), p.179-181
Main Authors: Allais, Gianni, Rolando, Sara, Schiapparelli, Paola, Airola, Gisella, Borgogno, Paola, Mana, Ornella, Benedetto, Chiara
Format: Article
Language:English
Subjects:
Adult
Brief Communication
Carbazoles - administration & dosage
Carbazoles - adverse effects
Drug Therapy, Combination
Female
Humans
Ketoprofen - administration & dosage
Ketoprofen - adverse effects
Ketoprofen - analogs & derivatives
Medicine
Medicine & Public Health
Menstrual Cycle
Middle Aged
Migraine
Migraine Disorders - drug therapy
Migraine Disorders - etiology
Neurology
Neuroradiology
Neurosciences
Neurosurgery
Psychiatry
Tromethamine - administration & dosage
Tromethamine - adverse effects
Tryptamines - administration & dosage
Tryptamines - adverse effects
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:At least 50 % of female migraineurs experience migraine associated with the perimenstrual period, even though they may also suffer from attacks at other times of the cycle (menstrually related migraine, MRM). MRM attacks tend to be longer and more intense than those arising in other phases of the menstrual cycle, and are often aggravated by more pronounced vegetative phenomena. In this open preliminary trial, we tested the efficacy of associating frovatriptan and dexketoprofen for the treatment of an acute attack of MRM, diagnosed according to the criteria of the International Headache Society, in 24 patients between 19 and 45 years of age (mean 31.33 ± 7.33). Twenty-one of them completed the study. Pain relief was achieved by 76 % of patients at 2 h and by 86 % at 4 h. A pain-free state was achieved by 48 % at 2 h and by 62 % at 4 h from taking the product. A pain-free state at 24 h was present in 76 % of MRM sufferers, 33 % of whom showed a sustained pain-free state at 24 h. A rescue medication was needed by eight patients. While decidedly encouraging, the data of this study obviously need confirmation with double blind studies involving a greater number of patients.
ISSN:1590-1874
1590-3478
DOI:10.1007/s10072-013-1390-0